Carving REMS Out of Oncology? FDA, ASCO Plan Follow-Up Workshop

FDA and the oncology community will continue discussions about the role of REMS in cancer care. The agency is clearly taking pushback from providers seriously.

The Food & Drug Administration and the American Society of Clinical Oncology will continue discussing the implications of Risk Evaluation & Mitigation Strategies for cancer therapies during an upcoming workshop.

FDA Office of Oncology Director Richard Pazdur disclosed plans for the upcoming workshop during the Institute of Medicine's National Cancer...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet